ASGR1: Asialoglycoprotein receptor 1
Transmembrane protein predominantly expressed on hepatocytes that plays a key role in endocytosis of plasma glycoproteins that lack terminal sialic acid residues.
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on ASGR1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Other 2
| Vupanorsen | Phase 2 | Ionis Pharmaceuticals | Oligonucleotide | Binding agentAsialoglycoprotein receptor 1 binding agent | 0 |
| Vupanorsen sodium | Phase 1 | — | Oligonucleotide | Binding agentAsialoglycoprotein receptor 1 binding agent | 0 |
- Hypercholesterolemia0.46
- Metabolic disease0.39
- Response to statin0.34
- Hyperlipidemia0.33
- Inherited lipid metabolism disorder0.33
- Familial hyperlipidemia0.25
- Hepatocellular carcinoma0.11
- Non-alcoholic fatty liver0.10
- Neoplasm0.10
- Type 2 diabetes mellitus0.10
- Hypertriglyceridemia0.10
- Autoimmune hepatitis0.09
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2084, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P07306, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets